- Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
- Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
- Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
- Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
- Can-Fite Granted Key NASH Patent in Israel
- Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
- Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
As of last trade,
Can Fite Biopharma Ltd (CF5B:STU) traded at 0.845, 15.75% above the 52 week low of 0.73 set on May 12, 2022.
0.73May 12 20222.08Dec 20 2021
Data delayed at least 15 minutes, as of Jun 30 2022.